FDA
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC): "today’s move seems like an over-reaction"
-
-
-
-
-
-
-
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update
-
-
-
-
-
-
-
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
-
-
-
-
-
-
-
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
-
-
-
-
-
-
-
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
-
-
-
-
-
-
-
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update
-
-
-
-
-
-
-
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
-
329,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

